New drug, Savella, brings hope for fibromyalgia patients

From the Fibromyalgia FMS Global News Desk of Jeanne Hambleton

By Marty Clear, Times Correspondent 
Posted: Feb 20, 2009 04:46 PM
Courtesy of tampabay.com St Petersburg Times

Hard to define and even harder to treat, fibromyalgia has become one of the most controversial medical conditions of the past quarter-century. Affecting an estimated 5.8 million Americans, it has been recognized as a disease by the American Medical Association since 1987. But because its most significant symptoms are pain and fatigue, with no obvious cause, FM patients — most of whom are women — can sometimes find that they’re not taken seriously even by some medical professionals.

St. Petersburg geriatrician and fibromyalgia expert Dr. Mildred Farmer says there’s new hope on the horizon for FM sufferers. Meridien Research, the company she co-founded in 1990, was one of the institutions that tested the efficacy and safety of a new fibromyalgia medication called Savella that was recently approved by the FDA and should be on the market later this year. It’s just the third anti-FM medication approved by the FDA, following Cymbalta and Lyrica.

Savella is already being prescribed in Europe as an antidepressant, but Meridien Research and other test sites across the country were looking at how it could help FM sufferers by affecting norepinephrine, a central nervous system neurotransmitter. Neither Farmer nor her company has a financial interest in Savella or the company that makes it, Cypress Bioscience.

What is fibromyalgia?

Essentially, it’s a collection of symptoms, a pain syndrome that is otherwise non-specific. Some people have aches and pains and not much fatigue, and some people have mostly the chronic fatigue and not as much pain. It could spring from a variety of causes.


How can you diagnose something that’s so elusive?

You must have widespread pain, in all four quadrants of the body, and it must be chronic. It’s characterized by the presence of trigger points. When you press on one of these points, they cause pain. It’s the presence of these trigger points and widespread pain, and the absence of joint and muscle pain, that makes fibromyalgia. It can be very subtle, and you might not even know you have it.

Who’s most likely to suffer from fibromyalgia?

It’s more common in women than men, and nobody knows why. I’ve read estimates that the ratio is 9 to 1. I wouldn’t be able to verify that, but it’s in that ballpark. Most of my fibromyalgia patients had a pain incident that preceded it — a car accident, a blow to the head. My usual patient is someone who has had back surgery. There’s also a genetic component, but it’s not just one gene, it’s a combination of genes.


How has it traditionally been treated?

What’s been happening for a long time is that rheumatologists have been treating fibromyalgia as a muscular-skeletal condition, and now it’s recognized as neuro-muscular. Traditional pain medications don’t do much. Non-steroidal anti-inflammatories, muscle relaxants, tricyclic antidepressants and exercise have all been somewhat effective, but different patients respond to different treatments. Even though the antidepressants can work, fibromyalgia is not depression. The patient may feel depressed, because of the chronic pain and because maybe no one believes her, but antidepressants can be effective for fibromyalgia itself.

Is Savella a dramatic breakthrough or just one more weapon in the arsenal?

In a way it’s just one more weapon. But the anti-fibromyalgia arsenal is so incredibly limited that even one additional weapon is significant.

What’s different about Savella?

Savella has more norepinephrine activity, and antidepressants with more norepinephrine activity seem to be more effective in treating pain. But there’s not been a head-to-head comparison of Cymbalta and this drug, so we can’t say this is better.

© 2009 · All Rights Reserved · St. Petersburg Times
490 First Avenue South · St. Petersburg, FL 33701 · 727-893-8111
http://www.tampabay.com/news/health/medicine/article977812.ece

Advertisements

About jeanne hambleton

Journalist-wordsmith, former reporter, columnist, film critic, editor, Town Clerk and then fibromite and eventer with 5 conferences done and dusted. Interested in all health and well being issues, passionate about research to find a cure and cause for fibromyalgia. Member LinkedIn. Worked for 4 years with FMA UK as Regional Coordinator for SW and SE,and Chair for FMS SAS the Sussex and Surrey FM umbrella charity and Chair Folly Pogs Fibromyalgia Research UK - finding funding for our "cause for a cure" and President and co ordinator of National FM Conferences. Just finished last national annual Fibromyalgia Conference Weekend. This was another success with speakers from the States . Next year's conference in Chichester Park Hotel, West Sussex, will be April 24/27 2015 and bookings are coming in from those who raved about the event every year. I am very busy but happy to produce articles for publication. News Editor of FMS Global News on line but a bit behind due to conference. A workaholic beyond redemption! The future - who knows? Open to offers with payment. Versatile and looking for a regular paid column - you call the tune and I will play the pipes.
This entry was posted in 13606, 16816416, 16816701, Awareness, Chronic Fatigue Syndrome, Chronic Pain, Clinical, Drugs, Europe, feed://feedproxy.google.com/bydls, Feeds, Fibrohugs, Fibrohugs News, Fibromyalgia, Fibromyalgia Blogs, Fibromyalgia News, Fibromyalgia News Southeast Asia, Fibromyalgia Press Releases, FM, FM drug companies, FMS, FMS Global News, Health, Health Care, http://feedburner.google.com/fb, http://feedburner.google.com/fbX, http://www.medpagetoday.com/PainManagement/PainManagement/tb/12867, London, London UK, London UK Feed, Medical, Medical Research, News, News UK, News USA, Pharmacologic, Pharmacological, Research, RSS, RSS Feeds, Uncategorized, US, USA, Washington D.C. City Feed, Washington DC, World, World News, World Wide, Worldwide and tagged , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s